Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
VVertex Pharmaceuticals Incorporated logo
VRTXNASDAQ

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated
Loading price data…
Loading price data…
Chart type
Interval
Moving averages
Up/down colors

Share screenshot

Recent & upcoming events

Aug 4
Filing Time TBD
Quarterly report (10-Q) filing due (est.)
Add to Google Calendar
Aug 3
Earnings 16:30
Q2 earnings
Add to Google Calendar
Earnings 16:30
Earnings call (第2四半期)
Add to Google Calendar
May 4
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Feb 12
Earnings Time TBD
Full-year earnings
Add to Google Calendar
2025
Nov 3
Earnings Time TBD
Q3 earnings
Add to Google Calendar
Aug 4
Earnings Time TBD
Q2 earnings
Add to Google Calendar
May 5
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Feb 10
Earnings Time TBD
Full-year earnings
Add to Google Calendar
Nov 2
Est.
Earnings 16:05 approx.
Q3 earnings (predicted)
Add to Google Calendar
2027
Feb 1
Est.
Earnings 16:05 approx.
FY earnings (predicted)
Add to Google Calendar
Feb 15
Est.
Filing Time TBD
Annual report (10-K) filing due (est.)
Add to Google Calendar
May 13
Est.
Shareholder meeting Time TBD
Annual meeting (est.)
Add to Google Calendar

KPI highlights

FY25
Revenue $12.00B YoY +8.9%
Operating income $4.17B margin 34.8%
Net income $3.95B YoY —
EPS $15.46 YoY —
P/E 26.4× Slightly rich Rough PER guide (a simplified band — fair value varies by industry and growth stage): <10 Cheap / 10–15 Slightly cheap / 15–22 Fair / 22–35 Slightly rich / ≥35 Rich
ROE 21.2% Equity ratio 73% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Quarterly fundamentals

Income & cash flow Unit: $1M
Quarter FY24 Q4FY25 Q1FY25 Q2FY25 Q3FY25 Q4FY26 Q1
Revenue 2,9122,7702,9653,0763,1902,987
Operating income -3,5161,0311,1541,2391,1301,139
Net income 9136461,0331,0831,1911,031
Operating CF 1,0624059739471,4251,184

F-Score (Piotroski)

5/9 1 of 9 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 15.4%
✓ Positive operating cash flow $3.63B
✓ ROA improved YoY -2.4% → 15.4%
✗ Operating CF exceeds net income (accrual quality) OCF $3.63B / net income $3.95B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 72.8% → 72.8%
✓ Current ratio improved 2.69× → 2.90×
✓ No dilution (shares outstanding did not increase) 256,940,382 → 253,991,224
— Gross margin improved No data
✗ Asset turnover improved 0.49× → 0.47×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio 72.8%
Current ratio 2.9×
Years of positive operating CF 9 of last 12 yrs
Payout ratio 0%
Latest fiscal year result Profit (net income $3.95B)

Performance history

Last 10 years
$0.0B$3.0B$6.0B$9.0B$12.0B FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Income & assets

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue 1,7022,4893,0484,1636,2067,5748,9319,86911,02012,001
Operating income 9.941236351,1982,8562,7824,3073,832-2334,173
Ordinary income ——————————
Net income -1122632,0971,1772,7122,3423,3223,620-5363,953
Total assets 2,8973,5466,2468,31811,75213,43318,15122,73022,53325,643
Equity 1,1572,0294,4356,0858,68710,10013,91317,58016,41018,666

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
EPS $-0.46$1.06$8.24$4.58$10.44$9.09$12.97$14.05$-2.08$15.46
ROE -9.7%13.0%47.3%19.3%31.2%23.2%23.9%20.6%-3.3%21.2%
Operating CF 2368451,2701,5693,2542,6444,1303,537-4933,631
Investing CF 51.2-483-202-1,23599.4-341-321-3,142-3,770-945
Financing CF 13368.4-71.2127-505-1,478-67.7-562-1,495-2,261
FCF ————2,9942,4093,9253,279-9783,194

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: SEC EDGAR (10-K, etc.) (fetched 2026-07-03) *Some metrics supplemented from additional sources

Key financial metrics

High ROE ✓ 3-year revenue growth ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data